BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Day In Review: Novartis Corporation (NVS) Devours Brit Biotech


6/7/2006 6:58:09 PM

June 7, 2006 – Novartis struck a deal to buy British antibody biotech NeuTec for $569 million; Abbott Labs received European approval for Humira to treat arthritic inflammation of the spine; a periodontitis drug candidate from CombinatoRx failed an inflammation test; Kos completed randomization in Phase III trials of Icatiban; Discovery Labs withdrew its request for European approval of Surfaxin; Vical received another $2.6 million from the NIH to continue developing its DNA-based bird-flu vaccine; Peregrine said that bavituximab was effective as a monotherapy against hepatitis C; European regulators will consider Xyotax, a cancer drug from Cell Therapeutics, on the basis of non-inferiority; Dendreon touted a positive article in the journal Cancer about Provenge; Schering extended the indication in Europe for Betaferon to include early-stage multiple sclerosis; GlaxoSmithKline partnered with Galapagos to develop osteoarthritis drugs; and Martek jumped higher after reporting an 83% increase in second quarter profit. The Centient Biotech 200™ ended 3 points lower at 3634.57, a drop of .07%. More details...

Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES